Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2004;42:57-60; doi:10.1136/dtb.2004.42857
Copyright © 2004 by the BMJ Publishing Group Ltd.

Which atypical antipsychotic for schizophrenia?

Relevant BNF section: 4.2.1

Until the early 1990s, first-line drug therapy for patients with acute schizophrenia was usually a traditional antipsychotic, such as haloperidol. As recently as 1997, we recommended that newer, so-called 'atypical' antipsychotic drugs, such as olanzapine and risperidone, should be reserved for patients unable to tolerate traditional drugs.1,2 Now, atypical antipsychotics are widely regarded as better than traditional drugs, being generally less likely to cause troublesome extrapyramidal effects or hyperprolactinaemia.3,4 Current atypical antipsychotics differ from one another in important respects. Here we consider how important differences in their unwanted-effect profiles may influence the choice between these drugs for patients with schizophrenia.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • OSBORN, D. P. J., NAZARETH, I., KING, M. B. (2006). Risk for coronary heart disease in people with severe mental illness: Cross-sectional comparative study in primary care. Br. J. Psychiatry 188: 271-277 [Abstract] [Full Text]  
  • Turner, T. H. (2004). Long term outcome of treating schizophrenia. BMJ 329: 1058-1059 [Full Text]